0000000000125613

AUTHOR

Andreas Trumpp

0000-0002-6212-3466

showing 6 related works from this author

Hematopoietic stem cell quiescence and function are controlled by the CYLD–TRAF2–p38MAPK pathway

2015

Tesio at al. identify a novel pathway controlled by the tumor suppressor and deubiquitinase cylindromatosis (CYLD), which is involved in the regulation of hematopoietic stem cell quiescence and repopulation potential.

TRAF2Tumor suppressor geneMAP Kinase Signaling SystemImmunologyRegulatorBiologyp38 Mitogen-Activated Protein KinasesArticleMicemedicineAnimalsImmunology and AllergyMice KnockoutRegulation of gene expressionNF-kappa BHematopoietic stem cellCell BiologyHematopoietic Stem CellsTNF Receptor-Associated Factor 2PhenotypeDeubiquitinating Enzyme CYLDCell biologyCysteine EndopeptidasesHaematopoiesismedicine.anatomical_structureGene Expression RegulationMutationStem cellJournal of Experimental Medicine
researchProduct

In vivo fate mapping with SCL regulatory elements identifies progenitors for primitive and definitive hematopoiesis in mice.

2009

10 páginas, 6 figuras.-- et al.

Definitive hematopoiesisEmbryologyMyeloidPopulationConditional mouse modelIn vivo linage and fate tracingEmbryonic DevelopmentStem cell leukemia geneBiology03 medical and health sciencesMice0302 clinical medicineFate mappinghemic and lymphatic diseasesProto-Oncogene ProteinsCRE systemmedicineBasic Helix-Loop-Helix Transcription FactorsAnimalsCell LineageMesodermal blood cell specificationGene Knock-In TechniquesProgenitor celleducationGeneTetracycline systemT-Cell Acute Lymphocytic Leukemia Protein 1Primitive hematopoiesis030304 developmental biology0303 health scienceseducation.field_of_studyMicroscopy ConfocalStem CellsEmbryoFlow CytometryCell biologyHematopoiesisGastrulationHaematopoiesismedicine.anatomical_structureBlood cell precursors030220 oncology & carcinogenesisImmunologyIn vivo lineage markingDevelopmental BiologyMechanisms of development
researchProduct

Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma

2016

The devastating prognosis of patients with resectable pancreatic ductal adenocarcinoma (PDA) presents an urgent need for the development of therapeutic strategies targeting disseminated tumor cells. Until now, T-cell therapy has been scarcely pursued in PDA, due to the prevailing view that it represents a poorly immunogenic tumor.We systematically analyzed T-cell infiltrates in tumor biopsies from 127 patients with resectable PDA by means of immunohistochemistry, flow cytometry, T-cell receptor (TCR) deep-sequencing and functional analysis ofProminent T-cell infiltrates, as well as tertiary lymphoid structures harboring proliferating T-cells, were detected in the vast majority of biopsies f…

0301 basic medicinePathologymedicine.medical_specialtyT cell repertoirePancreatic ductal adenocarcinomaTertiary Lymphoid StructuresTumor-infiltrating lymphocyteseducationImmunologyBiology03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisMIATA Compliant Research PapermedicineImmunology and AllergyImmune infiltrateOncoImmunology
researchProduct

Instruction of haematopoietic lineage choices, evolution of transcriptional landscapes and cancer stem cell hierarchies derived from an AML1-ETO mous…

2013

The t(8;21) chromosomal translocation activates aberrant expression of the AML1-ETO (AE) fusion protein and is commonly associated with core binding factor acute myeloid leukaemia (CBF AML). Combining a conditional mouse model that closely resembles the slow evolution and the mosaic AE expression pattern of human t(8;21) CBF AML with global transcriptome sequencing, we find that disease progression was characterized by two principal pathogenic mechanisms. Initially, AE expression modified the lineage potential of haematopoietic stem cells (HSCs), resulting in the selective expansion of the myeloid compartment at the expense of normal erythro- and lymphopoiesis. This lineage skewing was foll…

cancer stem cellsCancer stem cells; Core binding factor acute myeloid leukaemia; Preclinical mouse model; Therapy target validation; Whole transcriptome sequencingMyeloidtherapy target validationOncogene Proteins FusionCloseupsBiologyGranulocyte-Macrophage Progenitor CellsTranslocation Geneticwhole transcriptome sequencingImmunophenotypingMiceGranulocyte-Macrophage Progenitor CellsCancer stem cellhemic and lymphatic diseasesmedicineAML1-ETOAnimalsCell Lineageacute myeloid leukaemiaLymphopoiesisProgenitor cellt(8;21)Research Articlespreclinical mouse modelGeneticsRegulation of gene expressionAntibiotics AntineoplasticSequence Analysis RNAcore binding factor acute myeloid leukaemiainducible mouse-modelHematopoietic Stem CellsMice Inbred C57BLDisease Models AnimalLeukemia Myeloid AcuteHaematopoiesisPhenotypemedicine.anatomical_structureGene Expression RegulationDoxorubicinCancer researchNeoplastic Stem CellsMolecular MedicineStem cell
researchProduct

Wnt1 is an Lrp5-independent bone-anabolic Wnt ligand.

2018

Wnt signaling is important for proper embryonic development, shaping cell fate and migration, stem cell renewal, and organ and tissue formation. Here, Luther et al. investigated the role of Wnt1 in osteoporosis. Patients with early-onset osteoporosis and with WNT1 mutations had low bone turnover and high fracture rates, and loss of Wnt1 activity caused fracture and osteoporosis in mice. Inducing Wnt1 in bone-forming cells increased bone mass in aged mice, and this process did not require Lrp5, a co-receptor involved in Wnt signaling. This study identifies Wnt1 as an anabolic (bone building) factor and suggests that it might be a therapeutic target for osteoporosis.WNT1 mutations in humans a…

0301 basic medicinemedicine.medical_specialtyAginganimal structuresAnabolismCellular differentiationOsteoporosis030209 endocrinology & metabolismMice TransgenicWnt1 ProteinLigandsBone and BonesBone remodeling03 medical and health sciencesFractures Bone0302 clinical medicineAnabolic AgentsOsteogenesisInternal medicineCortical BoneMedicineAnimalsHumansTransgenesOsteoblastsbusiness.industryIncidenceWnt signaling pathwayLRP5OsteoblastCell DifferentiationGeneral MedicineOrgan Sizemedicine.disease030104 developmental biologyEndocrinologymedicine.anatomical_structureLow Density Lipoprotein Receptor-Related Protein-5Osteogenesis imperfectaembryonic structuresMutationBone RemodelingbusinessScience translational medicine
researchProduct

Hematopoietic Stem Cells Reversibly Switch from Dormancy to Self-Renewal during Homeostasis and Repair

2008

Bone marrow hematopoietic stem cells (HSCs) are crucial to maintain lifelong production of all blood cells. Although HSCs divide infrequently, it is thought that the entire HSC pool turns over every few weeks, suggesting that HSCs regularly enter and exit cell cycle. Here, we combine flow cytometry with label-retaining assays (BrdU and histone H2B-GFP) to identify a population of dormant mouse HSCs (d-HSCs) within the lin(-)Sca1(+)cKit(+)CD150(+)CD48(-)CD34(-) population. Computational modeling suggests that d-HSCs divide about every 145 days, or five times per lifetime. d-HSCs harbor the vast majority of multilineage long-term self-renewal activity. While they form a silent reservoir of th…

BromouracilProliferationCellCD34CELLCYCLEQuiescenceSelf renewalMice0302 clinical medicineLongBone MarrowHomeostasisCancereducation.field_of_study0303 health sciencesProgenitor Cellshemic and immune systemsCell cycleCell biologyAdult Stem CellsHaematopoiesismedicine.anatomical_structure030220 oncology & carcinogenesisFluorouracilStem cellGreen Fluorescent ProteinsPopulationMice TransgenicCycleBiologyGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesmedicineAnimalsProgenitor celleducationUridine030304 developmental biologyMouse ModelBiochemistry Genetics and Molecular Biology(all)Osteoblastic NicheHematopoietic Stem CellsSTEMCELLAntigens DifferentiationMarrowIn-VitroImmunologyDormancyBone marrowHomeostasisCell
researchProduct